Shanghai - Delayed Quote CNY
Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS)
54.29
-0.12
(-0.22%)
At close: 3:00:03 PM GMT+8
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Zhang Xiaolin Ph.D. | GM & Chairman | -- | -- | 1964 |
| Mr. Lyu Hongbin M.B.A. | CFO & Board Secretary | -- | -- | 1978 |
| Ms. Zhiwei Zhang | Deputy GM, VP & Head of Operations | -- | -- | 1982 |
| Dr. Qingbei Zeng | Deputy GM, Chief Scientist & Senior VP | -- | -- | 1962 |
| Dr. Zhenfan Yang M.D., Ph.D. | Deputy GM & Chief Medical Officer | -- | -- | 1968 |
| Ms. Qingyi Wu | Deputy GM & Chief Commercial Officer | -- | -- | 1974 |
| Dr. Honchung Tsui | Deputy GM, Senior VP & Head of Medicinal Chemistry Department | -- | -- | 1968 |
| Dr. Shih-Ying Chang Ph.D. | Deputy GM, VP & Head of Chemistry, Production and Control Department | -- | -- | 1963 |
| Ms. Suqin Chen | Deputy GM & Senior VP of Clinical Operations | -- | -- | 1967 |
| Mr. Weijun Qiao | VP & Head of Registration Affairs | -- | -- | 1966 |
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
199 Liangjing Rd
Zhangjiang Hi-Tech Park Pudong District
Shanghai, 201203
China
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical trials for the treatment of solid tumors. The company was founded in 2017 and is based in Shanghai, China.
Corporate Governance
Dizal (Jiangsu) Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available